Most Shorted Stocks
CERT is part of our most shorted stocks screen list, indicating it has a high short interest.
CERTARA INC (CERT) Stock Price & Overview
NASDAQ:CERT • US15687V1098
Current stock price
6.09 USD
+0.27 (+4.64%)
Last:
The current stock price of CERT is 6.09 USD. Today CERT is up by 4.64%. In the past month the price decreased by -10.32%. In the past year, price decreased by -58.87%.
CERT Key Statistics
52-Week Range5.19 - 15.38
Current CERT stock price positioned within its 52-week range.
1-Month Range5.19 - 6.8
Current CERT stock price positioned within its 1-month range.
- Market Cap
- 933.78M
- P/E
- 13.84
- Fwd P/E
- 13.25
- EPS (TTM)
- 0.44
- Dividend Yield
- N/A
CERT Stock Performance
Today
+4.64%
1 Week
+3.56%
1 Month
-10.32%
3 Months
-38.80%
Longer-term
6 Months -51.38%
1 Year -58.87%
2 Years -65.98%
3 Years -75.92%
5 Years -81.70%
10 Years N/A
CERT Stock Chart
CERT Stock Screens
CERT currently appears in the following ChartMill screener lists.
CERT Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CERT. When comparing the yearly performance of all stocks, CERT is a bad performer in the overall market: 94.85% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
CERT Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to CERT. CERT has only an average score on both its financial health and profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CERT Earnings
On February 26, 2026 CERT reported an EPS of 0.09 and a revenue of 103.65M. The company missed EPS expectations (-21.15% surprise) and missed revenue expectations (-1.53% surprise).
Next Earnings DateMay 4, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported$0.09
Revenue Reported103.648M
EPS Surprise -21.15%
Revenue Surprise -1.53%
CERT Forecast & Estimates
20 analysts have analysed CERT and the average price target is 9.52 USD. This implies a price increase of 56.32% is expected in the next year compared to the current price of 6.09.
For the next year, analysts expect an EPS growth of 4.43% and a revenue growth 2.3% for CERT
Analysts
Analysts76
Price Target9.52 (56.32%)
EPS Next Y4.43%
Revenue Next Year2.3%
CERT Groups
Sector & Classification
CERT Financial Highlights
Over the last trailing twelve months CERT reported a non-GAAP Earnings per Share(EPS) of 0.44. The EPS decreased by -2.22% compared to the year before.
Income Statements
Revenue(TTM)418.84M
Net Income(TTM)-1.59M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.1% | ||
| ROE | -0.15% | ||
| Debt/Equity | 0.27 |
Chartmill High Growth Momentum
EPS Q2Q%-40%
Sales Q2Q%3.28%
EPS 1Y (TTM)-2.22%
Revenue 1Y (TTM)8.75%
CERT Ownership
Ownership
Inst Owners95.57%
Shares153.33M
Float113.29M
Ins Owners0.79%
Short Float %19.68%
Short Ratio5.6
CERT Competitors/Peers
The largest stocks on the US markets in the "Health Care Technology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 18.26 | 25.984B | ||
| WAY | WAYSTAR HOLDING CORP | 14.15 | 4.299B | ||
| DOCS | DOXIMITY INC-CLASS A | 14.15 | 4.11B | ||
| HTFL | HEARTFLOW INC | N/A | 2.491B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 140.92 | 1.158B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.15B | ||
| TDOC | TELADOC HEALTH INC | N/A | 934.816M | ||
| SDGR | SCHRODINGER INC | N/A | 879.315M | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 6.97 | 763.931M | ||
| HSTM | HEALTHSTREAM INC | 27.51 | 597.182M | ||
| PHR | PHREESIA INC | 14.46 | 522.536M | ||
| TBRG | TRUBRIDGE INC | 9.26 | 321.161M |
Related stock screener links
View all stocks in the Health Care Technology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CERT
Company Profile
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. The company is headquartered in Radnor, Pennsylvania and currently employs 1,515 full-time employees. The company went IPO on 2020-12-11. The company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. The company delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. The company offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
Company Info
IPO: 2020-12-11
CERTARA INC
4 Radnor Corporate Center, Suite 350
Radnor PENNSYLVANIA 08540 US
CEO: William F. Feehery
Employees: 1546
Phone: 18009279800
CERTARA INC / CERT FAQ
What does CERT do?
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. The company is headquartered in Radnor, Pennsylvania and currently employs 1,515 full-time employees. The company went IPO on 2020-12-11. The company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. The company delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. The company offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
What is the stock price of CERTARA INC today?
The current stock price of CERT is 6.09 USD. The price increased by 4.64% in the last trading session.
Does CERT stock pay dividends?
CERT does not pay a dividend.
How is the ChartMill rating for CERTARA INC?
CERT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the market expecting CERT stock to perform?
20 analysts have analysed CERT and the average price target is 9.52 USD. This implies a price increase of 56.32% is expected in the next year compared to the current price of 6.09.
What is the next earnings date for CERT stock?
CERTARA INC (CERT) will report earnings on 2026-05-04, after the market close.
What is the Short Interest ratio of CERTARA INC (CERT) stock?
The outstanding short interest for CERTARA INC (CERT) is 19.68% of its float.